Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NewCo Ventures
Unknown
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
NewCo Ventures accelerates development of novel treatments—especially for rare diseases—by partnering with pharma companies to license partially developed molecules. The company advances these assets through registration and marketing, often via dedicated spin-out companies such as Cheetah Therapeutics (oncology focus). Their model addresses unmet medical needs by bridging gaps left by traditional pharma development cycles[3].
- Therapeutic areas
- OtherOncologyRare Diseases
- Modalities
- Small moleculesPotentially biologics
- Industry
- Biotech
02
Partnerships
Collaborates with pharmaceutical originators who have partially progressed molecules available for further development/licensing-in partnerships
Beyond the preview
Go deeper on NewCo Ventures.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NewCo Ventures.